ESR1 and breast carcinoma: In ER–negative, AR–positive breast cancers, activated androgen–AR complexes enter the nucleus and bind to androgen response elements in chromatin to induce tumor cell proliferation, whereas in ER–positive, AR–positive breast cancers, activated AR competes with ER to bind estrogen response elements in chromatin and induces apoptosis [21].